Abstract
Purpose
The aim of this study was to ascertain the effect size of statins in modulating plasma uric acid concentrations.
Data Sources
A search was undertaken of the MEDLINE, SCOPUS, Web of Science and Google Scholar electronic databases.
Study Selection
Studies meeting the following criteria were included: (i) randomized controlled trials with either a parallel or crossover design; (ii) investigated the impact of statin therapy on plasma uric acid concentrations; and (iii) presentation of sufficient information on uric acid values at baseline and at the end of follow-up in each group, or presenting the net change.
Data Synthesis
The present meta-analysis suggested a significant reduction in plasma uric acid levels following statin therapy; however, this does not seem to be a class effect as subgroup analysis revealed a significant reduction with atorvastatin and simvastatin only, and not with pravastatin and rosuvastatin.
Conclusions
Atorvastatin and simvastatin, but not the other statins, can reduce serum uric acid levels.
Similar content being viewed by others
References
Tomita M, Mizuno S, Yamanaka H, et al. Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers. J Epidemiol. 2000;10:403–9.
Reunanen A, Takkunen H, Knekt P, Aromaa A. Hyperuricemia as a risk factor for cardiovascular mortality. Acta Med Scand Suppl. 1982;668:49–59.
Levine W, Dyer AR, Shekelle RB, Schoenberger JA, Stamler J. Serum uric acid and 11.5-year mortality of middle-aged women: findings of the Chicago Heart Association Detection Project in Industry. J Clin Epidemiol. 1989;42(3):257–67.
Lazzeri C, Valente S, Chiostri M, Sori A, Bernardo P, Gensini GF. Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: its prognostic role and relation with inflammatory markers: a single center experience. Int J Cardiol. 2010;138(2):206–9.
Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J. 2012;33:1635–701.
Niskanen LK, Laaksonen DE, Nyyssönen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. Arch Intern Med. 2004;164(14):1546–51.
Testa A, Prudente S, Leonardis D, et al. A genetic marker of hyperuricemia predicts cardiovascular events in a meta-analysis of three cohort studies in high risk patients. Nutr Metab Cardiovasc Dis. 2015;25(12):1087–94.
Takahashi S, Yamamoto T, Moriwaki Y, Tsutsumi Z, Higashino K. Impaired lipoprotein metabolism in patients with primary gout-influence of alcohol intake and body weight. Br J Rheumatol. 1994;33:731–4.
Takahashi S, Moriwaki Y, Tsutsumi Z, Yamakita J, Yamamoto T, Hada T. Increased visceral fat accumulation further aggravates the risks of insulin resistance in gout. Metabolism. 2001;50:393–8.
Derosa G, Maffioli P, Sahebkar A. Plasma uric acid concentrations are reduced by fenofibrate: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;102:63–70.
Stancu C, Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001;5(4):378–87.
Kawashiri MA, Yamagishi M, Sakamoto T, et al. COSMOS Investigators. Impact of intensive lipid lowering on lipid profiles over time and tolerability in stable coronary artery disease: insights from a subanalysis of the coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS). Cardiovasc Ther. 2013;31(6):335–43.
Wiliński J, Dabrowski M. Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3227 patients. Przegl Lek. 2013;70(6):373–6.
Sahebkar A, Rathouska J, Simental-Mendía LE, Nachtigal P. Statin therapy and plasma cortisol concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacol Res. 2015;103:17–25.
Sahebkar A, Simental-Mendía LE, Pedone C, et al. Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials. Br J Clin Pharmacol. 2016;81(5):807–18.
Sahebkar A, Serban C, Mikhailidis DP, Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group, et al. Association between statin use and plasma D-dimer levels. A systematic review and meta-analysis of randomised controlled trials. Thromb Haemost. 2015;114(3):546–57.
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.
Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions. Version 5.0.2. London: The Cochrane Collaboration; 2009.
Borenstein M, Hedges L, Higgins J, et al. Comprehensive meta-analysis. Version 2. Englewood; Biostat: 2005.
Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. West Sussex: Wiley; 2000.
Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50–73.
Greenhouse J, Iyengar S. Sensitivity analyses and diagnostics. In: Cooper HM, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation; 1994.
Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56:455–63.
Fassett RG, Robertson IK, Ball MJ, Geraghty DP, Coombes JS. Effects of atorvastatin on oxidative stress in chronic kidney disease. Nephrology (Carlton). 2015. doi:10.1111/nep.12502.
Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism. 2005;54(8):1065–74.
Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. Heart Vessels. 2008;23(2):91–5.
Athyros VG, Elisaf M, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, GREACE Study Collaborative Group, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis. 2004;43(4):589–99.
Glorioso N, Troffa C, Filigheddu F, et al. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia. Hypertension. 1999;34(6):1281–6.
Gleim G, Ballantyne CM, Liu N, Thompson-Bell S, McCrary Sisk C, Pasternak RC, et al. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol. 2009;16(2):90–7.
Tam LS, Li EK, Shang Q, et al. Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial. Scand J Rheumatol. 2011;40(6):411–21.
Tousoulis D, Andreou I, Tsiatas M, et al. Effects of rosuvastatin and allopurinol on circulating endothelial progenitor cells in patients with congestive heart failure: the impact of inflammatory process and oxidative stress. Atherosclerosis. 2011;214(1):151–7.
Palomäki A, Malminiemi K, Metsä-Ketelä T. Enhanced oxidizability of ubiquinol and alpha-tocopherol during lovastatin treatment. FEBS Lett. 1997;410(2–3):254–8.
Atsukawa M, Tsubota A, Shimada N, Kondo C, Itokawa N, Nakagawa A, et al. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol. 2014;26(7):781–7.
Fazio S, Guyton JR, Lin J, Tomassini JE, Shah A, Tershakovec AM. Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. Diabetes Obes Metab. 2010;12(11):983–93.
Jacobson TA, Chin MM, Fromell GJ, Jokubaitis LA, Amorosa LF. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol. 1994;74(2):149–54.
McKenney J, Bays H, Gleim G, Mitchel Y, Kuznetsova O, Sapre A, et al. Safety and tolerability of extended-release niacin-laropiprant: pooled analyses for 11,310 patients in 12 controlled clinical trials. J Clin Lipidol. 2015;9(3):313–25.
Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. Am J Med. 2001;111(5):390–400.
Milionis HJ, Kakafika AI, Tsouli SG, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. Am Heart J. 2004;148(4):635–40.
Cappuccio FP, Strazzullo P, Farinaro E, Trevisan M. Uric acid metabolism and tubular sodium handling. Results from a population-based study. JAMA. 1993;270(3):354–9.
Kose E, An T, Kikkawa A, Matsumoto Y, Hayashi H. Effects on serum uric acid by difference of the renal protective effects with atorvastatin and rosuvastatin in chronic kidney disease patients. Biol Pharm Bull. 2014;37(2):226–31.
Takagi H, Umemoto T. Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials. Int J Cardiol. 2012;157(2):255–7.
Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. Nucleosides Nucleotides Nucleic Acids. 2010;29(4–6):321–4.
Acknowledgments
No writing assistance was utilized in the preparation of this manuscript.
Author contributions
Design: Amirhossein Sahekbar. Conduct/data collection: All authors. Analysis: Amirhossein Sahekbar. Writing manuscript: All authors.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No external funding was used to conduct this work.
Conflict of interest
Giuseppe Derosa, Pamela Maffioli, Željko Reiner, Luis E. Simental-Mendía, and Amirhossein Sahebkar have no relevant affiliations or financial involvement with any organization or entity with a financial interest in, or financial conflict with, the subject matter or materials discussed in the manuscript, including employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Rights and permissions
About this article
Cite this article
Derosa, G., Maffioli, P., Reiner, Ž. et al. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. Drugs 76, 947–956 (2016). https://doi.org/10.1007/s40265-016-0591-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-016-0591-2